Robinson, Michael-Paul
Jung, Jinjoo http://orcid.org/0000-0001-5809-5792
Lopez-Barbosa, Natalia http://orcid.org/0000-0001-6599-0859
Chang, Matthew
Li, Mingji http://orcid.org/0000-0003-2455-3307
Jaroentomeechai, Thapakorn
Cox, Emily C.
Zheng, Xiaolu
Berkmen, Mehmet http://orcid.org/0000-0002-9579-9745
DeLisa, Matthew P. http://orcid.org/0000-0003-3226-1566
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (AI092969-01A1)
United States Department of Defense | Defense Threat Reduction Agency (HDTRA1-15-10052 and HDTRA1-20-10004)
National Science Foundation (CBET-1605242)
Article History
Received: 9 May 2020
Accepted: 1 June 2023
First Online: 14 June 2023
Competing interests
: M.P.D. has a competing interest in Gauntlet Bio, Inc., Glycobia, Inc., SwiftScale Biologics, Inc., UbiquiTx, Inc. and Versatope Therapeutics, Inc. M.P.D.’s interests are reviewed and managed by Cornell University in accordance with their conflict-of-interest policies. M.B. is employed by NEB, which commercializes SHuffle cells. All other authors declare no competing interests.